VERA
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Vera Therapeutics reported that TRUTAKNA stabilized eGFR and prevented kidney disease progression through two years in the final ORIGIN 3 analysis in IgA nephropathySep 15, 2026
- Vera Therapeutics received FDA accelerated approval for TRUTAKNA to treat adults with primary IgA nephropathyJul 8, 2026
- U.S. FDA granted Priority Review to Vera Therapeutics' BLA for atacicept in IgA NephropathyJan 7, 2026
- Vera Therapeutics announces Atacicept achieved 46% proteinuria reduction in Phase 3 ORIGIN trial for IgA nephropathyJun 2, 2025